Characterization of gut microbiota in patients with primary hepatocellular carcinoma received immune checkpoint inhibitors: A Chinese population-based studyOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
This study characterized the gut microbiota of patients with advanced primary hepatocellular carcinoma (HCC) who received immune checkpoint inhibitors (ICIs). Researchers amplified and sequenced the 16S rDNA V4 region on the MiSeq platform to profile bacterial composition. The goal was to determine whether specific gut bacterial taxa relate to how patients respond to ICI treatment.
Who was studied?
The study drew on an initial cohort of 65 patients with metastatic melanoma who were treated with ICIs at Fujian provincial geriatric hospital between August 2016 and June 2018. This cohort was used in the context of a larger Chinese population-based study of HCC patients with hepatitis B virus infection who received ICIs. Patients were later stratified into high versus low groups based on the median relative abundance of specific bacterial taxa in their gut microbiome.
What were the most important findings?
Gut microbiota diversity was found to be notably increased in HCC patients who received ICIs, a pattern attributed to negative feedback between microbial metabolic activity and host pathways. The Faecalibacterium genus was highlighted in the response group, while the Bacteroidales order stood out in the non-response group. Patients with high Faecalibacterium abundance had significantly prolonged progression-free survival (PFS) compared to those with low abundance.
What are the greatest implications of this study?
These findings suggest that gut microbiota composition, particularly Faecalibacterium abundance, may serve as a biomarker for predicting response and progression-free survival in HCC patients treated with immune checkpoint inhibitors. Because Faecalibacterium prausnitzii is a recognized butyrate-producing, anti-inflammatory commensal, its association with better outcomes points to a possible link between gut-derived anti-inflammatory activity and immunotherapy efficacy. This raises the possibility that modulating gut microbiota could become a strategy to improve ICI outcomes in liver cancer, though further studies are needed to establish causality.